Skip to main content
Signal8

Hemogenyx Pharmaceuticals Plc (HOPHF)

Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome. This novel approach seeks to condition patients for bone marrow transplants, offering a potential alternative to conventional chemotherapy and/or radiation treatments. Additionally, Hemogenyx is advancing HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to specifically identify and eradicate human AML-derived cells, demonstrated in both in vitro and in vivo studies. Its portfolio also features Human Postnatal Hematopoietic Endothelial Cells, a unique stem cell therapy intended for BM/HSC transplant applications. Established in 2012, the company maintains its headquarters in London, United Kingdom.

Sector: Biotechnology

Industry: Biotechnology

Hemogenyx Pharmaceuticals Plc logo

Hemogenyx Pharmaceuticals Plc

OTC:HOPHFHealthcare
Mkt Cap-
EV-
Float3.88M
O/S6.9M
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 3.88M · FMP free float

1.2K
Oct 30 (18d)prev 1.2K– 0.0%
999.99
Oct 30 (18d)prev 999.99– 0.0%
Borrow (IBKR)

The cost to borrow HOPHF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis6 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20261.2K sh
Oct 15, 20261.2K sh
Sep 30, 20261.1K sh
Sep 15, 2026105 sh
Feb 27, 2026117 sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume

FINRA publishes no off-exchange short volume for this symbol.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for HOPHF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 1,164 HOPHF shares were sold short (0.03% of a 3.88M-share float, 999.99 days to cover).